December 2, 2014: ACTTION Submits Letter of Intent to FDA for QUALITE-Pain

ACTTION has been assigned a Drug Development Tool number by FDA and submitted a Letter of Intent to FDA to begin development of the “QUALIfied for Therapeutic Evaluations of Pain” (QUALITE-Pain) instrument and then apply for its qualification as a Clinical Outcome Assessment. ACTTION is eagerly waiting for the FDA’s response and looks forward to developing an evidence-based and state-of-the-art approach for the assessment of pain intensity.